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A B S T R A C T
Background: Bioﬁlm is an impediment to wound healing as a consequence of its proven ability to impair
epithelialization, granulation tissue formation and normal inﬂammatory processes, as well as protecting
wound pathogens from antibiotics and antiseptics. With this in mind, a project was initiated to develop a
combined anti-bioﬁlm/antimicrobial technology that could be incorporated into a wound dressing to
maximize effectiveness against wound pathogens existing in their predominant bioﬁlm form.
Methods: Initially, a wide range of anti-bioﬁlm agents in combination with ionic silver were screened in a
rapid throughput in vitro bioﬁlm model. Selected agents were incorporated into a new wound dressing
format and subsequently tested in vitro against antibiotic-resistant pathogens in their most tolerant
bioﬁlm form.
Results: The combination of ionic silver with a metal chelating agent and a surfactant was shown to
produce a synergistic effect (referred to as Ag+ Technology) that substantially improved the antimicrobial
efﬁcacy of ionic silver against bioﬁlm pathogens in a simulated wound bioﬁlm model.
Conclusion: By combining anti-bioﬁlm and antimicrobial components that work in synergy to disrupt
bioﬁlm and expose associated wound pathogens to the antimicrobial action of ionic silver, it is
anticipated that this new technology incorporated into an advanced Hydroﬁber1 wound dressing will
contribute signiﬁcantly to managing bioﬁlm infections and encouraging healing in patients debilitated by
recalcitrant wounds.
ã 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Bacteria exist naturally and preferentially in a bioﬁlm mode of
life in which they are surface-attached and encased within a matrix
of self-produced extracellular polymeric substances (EPS) that
provides protection from environmental hostilities such as host
defences and biocides. The National Institutes of Health (NIH) has
estimated that greater than 80% of human infections involve
bacterial bioﬁlm [1].
Pathogenic bioﬁlm can arguably rank alongside antibiotic
resistance as being a major concern in healthcare and infectious
diseases today. Whereas bacterial resistance is a relatively recent
and largely genetically-induced response to external attack from
antibiotics, bioﬁlm is a natural, phenotypic state that enables
bacteria to tolerate exposure to external threats such as antibiotics
and antiseptics [2,3]. Ultimately, the existence of antibiotic-* Corresponding author.
E-mail address: phil.bowler@convatec.com (P.G. Bowler).
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2213-9095/ã 2016 The Authors. Published by Elsevier GmbH. This is an open access arresistant bacteria growing within bioﬁlm presents a real and
signiﬁcant danger to public health. With this in mind, there is a
clear need to facilitate the effectiveness of antibiotics and other
antimicrobial agents by utilizing anti-bioﬁlm strategies that can
disrupt bioﬁlm and expose the bacteria to more effective action of
antimicrobial agents.
Recently, bioﬁlm has been recognized as a cause of recalcitrance
and infection in chronic wounds, and as an explanation for the
frequent failure of antibiotics and antiseptics in these debilitating
conditions [4,5]. Ionic silver is an effective and broad-spectrum
topical antiseptic agent that is widely used in wound care to
manage local infection [6–8], but, as with antibiotics and other
antiseptics, its effectiveness against bioﬁlm-protected bacteria is
limited [9]. With a view to enhancing the clinical effectiveness of
ionic silver in bioﬁlm-impeded wounds, a project was undertaken
to identify safe and effective anti-bioﬁlm substances that could be
used in combination with ionic silver. The clinical hypothesis was
that if wound microﬂora in recalcitrant wounds could be trans-
formed from a predominantly bioﬁlm (tolerant) population to aticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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efﬁcacy of ionic silver is likely to be enhanced considerably. The
aim therefore, was to utilize carefully selected anti-bioﬁlm
substances to maximize the antimicrobial activity of ionic silver
in a commercially-available silver-containing Hydroﬁber1 dress-
ing, AQUACEL1 Ag Extra1.Table 1
The independent variables studied, their broad classiﬁcation (bold), type and/or examp2. Methods
2.1. Minimum bioﬁlm eradication concentration (MBEC)
This method was used to identify anti-bioﬁlm substances that
would work most effectively with ionic silver to enhance theles of compounds (lists of chemical/biochemical agents screened).
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AQUACEL1 Ag (SH).
First published in 1999, the MBEC method was designed as a
high-throughput in vitro method to measure antibiotic suscepti-
bility in the presence of bacterial bioﬁlm [10]. It has been adapted
here to investigate the efﬁcacy of compounds in conjunction with
ionic silver.
Test variables, which included bioﬁlm disrupting substances,
surfactants and pH (Table 1), were investigated individually or in
combination against a doubling-dilution gradient of ionic silver
(128 mg/ml reducing to 1 mg/ml). Brieﬂy, the method used 96-well
microtiter plates (wells) with lids with corresponding protruding
spikes (pegs) [Nunc, Denmark] (Fig. 2). Pseudomonas aeruginosa
(NCIMB 8626) in planktonic form (suspension) was inoculated into
each well (1 105 in 150 ml) and the peg lid was ﬁtted. Bioﬁlm
formation was encouraged by incubation with gentle agitation
(24 h/35 C/gyration). Pegs were then washed (2) to remove
planktonic bacteria and inserted into fresh wells containing the
test substance(s) (30 min, 35 C). Treated pegs were neutralized by
washing with isotonic saline (5), then placed into further wells
containing a growth medium (Mueller Hinton Broth, MHB) and
sonicated (5 min) to destroy residual bioﬁlm EPS, thus releasing
planktonic bacteria. The peg lid was then discarded and replaced
by a plain lid. Wells were incubated (24 h/35 C) and optical density
at 595 nm was then determined using a microtiter plate
spectrophotometer [Powerwave XS, BioTek Instruments Inc.].
Anti-bioﬁlm activity was determined semi-quantitatively by the
degree of opacity being proportional to bioﬁlm survival.
2.2. Gauze bioﬁlm model [11]—simulated use testing of the formulated
product
Having identiﬁed the anti-bioﬁlm substances that worked most
effectively with ionic silver to provide a combined anti-bioﬁlm/
antimicrobial effect, the anti-bioﬁlm silver-containing Hydro-
ﬁber1 dressing subsequently formulated (AQUACEL1 Ag+ Extra
[ABSH]) was compared with three other, commercially-available
silver-containing wound dressings (see Table 2) in a stringent in
vitro gauze bioﬁlm model. All three of the comparator silver-
containing dressings are widely used in wound care of which one
was the same silver-containing Hydroﬁber1 dressing without the
addition of anti-bioﬁlm substances.
This method was developed from the observation that
implanted gauze dressing in experimental wounds promoted
and prolonged infection [12] which was likely induced by bioﬁlm
formation on the gauze implant. All three dressings tested in this
model are indicated for use on wounds that are locally infected or
at risk of infection.
Mature P. aeruginosa (NCTC 13437) or community-associated
Methicillin-resistant Staphylococcus aureus (CA-MRSA, USA-300)Table 2
Test dressings (wound dressing details).
Dressing
Reference
Dressing Description (United Kingdom IFU description) 
SH AQUACEl1Ag ExtraTM
(ConvaTec Inc.)
Two layers of 1.2% ionic silver impregnated sod
ﬁbers.
ABSH AQUACEL1Ag+
ExtraTM
(ConvaTec Inc.)
Two layers of sodium carboxymethylcellulose im
by ethylenediaminetetra-acetic acid di-sodium 
regenerated cellulose ﬁbre.
SNA Silvercel1NA
(Systagenix)
Non-woven pad composed of high G (guluronic a
coated nylon ﬁbers, laminated to a perforated, n
AC7 Acticoat TM 7
(Smith & Nephew
Medical Limited)
A layered dressing consisting of two layers of a
nanocrystalline silver-coated, low adherent polbioﬁlm was grown by inoculating 1 106 CFU/ml in a nutrient-rich
medium onto pieces of sterile gauze [N-A knitted viscose primary
dressing (Systagenix)] and incubating (48 h/35 C/gyration)
(Fig. 1A). Bioﬁlm-gauze substrates (BGSs) were rinsed (2;
Fig. 1B) and the presence of bioﬁlm was conﬁrmed by environ-
mental scanning electron microscopy (ESEM, Quanta200, FEI)
(Fig. 1C) and confocal laser-scanning microscopy (CLSM, TCS SP2,
Leica) (Fig. 1D). BGSs were cut to 35 mm diameter circles and
transferred onto Tryptone Soy Agar contact plates (the simulated
wound bed) which were ﬁtted into a Perspex block covered with
dried leather (simulating peri-wound skin) (Fig. 2A). Test dressings
were placed over the BGS, hydrated with a simulated wound ﬂuid
[6] and covered with an adhesive secondary cover dressing
[AQUACELTM Foam Dressing, ConvaTec] (Fig. 2B and C). Test models
were then incubated for up to nine days, and after 4–5 days, BGSs
were re-inoculated with 1 105 CFU bacteria to challenge the
dressing’s ability to prevent bioﬁlm re-formation (Fig. 2E) over a
further 3–4 days. After 4 h and daily time points bioﬁlm-gauze
substrates (5 per treatment time per test dressing) were removed
(Fig. 2D), placed in neutralising broth and stomached (4 min, high
setting) to detach and disperse residual bioﬁlm. Quantitative
microbiological methods were then used to determine the
bioburden in the resultant suspension and hence calculate the
survival of bacteria in the BGSs.
3. Results
3.1. MBEC screening study
Three variables were studied: bioﬁlm disrupting substances,
surfactants and pH (Table 1). Approximately 250,000 potential
combinations were identiﬁed but this was reduced to 60,000
tests by eliminating potentially unsafe or chemically incompatible
options.
Of the bioﬁlm-disrupting substances, metal chelation and ion
exchange polymers performed most effectively in the MBEC
model. Enzymes that were considered were generally inhibited by
ionic silver; they interfered with antimicrobial activity, and were
strongly pH-dependent and were hence excluded from further
consideration. The bioﬁlm softening/solubilizing candidates were
ineffective and in many cases encouraged bioﬁlm proliferation. For
the surfactants, the majority of anionic surfactants were precipi-
tated by ionic silver and quaternary cationic surfactants were most
effective.
The optimum combination with ionic silver was the metal
chelating substance ethylenediaminetetra-acetic acid (EDTA), the
quaternary cationic surfactant benzethonium chloride and a pH of
approximately 5.5. None of the individual components showed
activity in isolation, but were strongly synergistic when brought
together.Silver Content
(by assay)
ium carboxymethylcellulose stitched together with strengthening 0.16 mg/cm2
(1.2% w/w dry)
pregnated with 1.2% ionic silver (an antimicrobial agent), enhanced
salt (EDTA) and benzethonium chloride, and strengthened by
0.16 mg/cm2
(1.2% w/w dry)
cid) alginate, carboxymethyl cellulose (CMC) and elemental silver-
on-adherent ethylene methyl acrylate (EMA) wound contact layer.
0.74 mg/cm2
(2.2% w/w)
bsorbent rayon/polyester leaved between three layers of elemental
yethylene net.
1.8 mg/cm2
(11.2% w/w)
Fig 1. P. aeruginosa bioﬁlm on gauze; rinsing of bioﬁlm gauze to remove planktonic bacteria; conﬁrmation of bioﬁlm on gauze using ESEM; confocal microscopy.
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Four silver-containing antimicrobial wound dressings were
tested (Table 2). The anti-bioﬁlm silver-containing Hydroﬁber1
dressing (ABSH) was the only antimicrobial dressing tested in this
in vitro model that was capable of killing a highly antibiotic-
resistant strain of S. aureus (CA-MRSA) in bioﬁlm form (Fig. 3). The
same silver-containing dressing without anti-bioﬁlm enhance-
ment (Ag+ Technology) (SH) was not able to eliminate CA-MRSA
bioﬁlm. Other high silver-content dressings (AC7 and SNA) were
ineffective against CA-MRSA bioﬁlm in this model.
The ABSH dressing was superior to SH against a multidrug
resistant P. aeruginosa bioﬁlm; AC7 and SNA dressings had no
antimicrobial/anti-bioﬁlm effect (Fig. 4). The ABSH dressing wasFig. 2. Gauze bioﬁlm model. Agar contact plate inserted into center of the model surrou
bioﬁlm-colonized wound bed (A); dressing placed over the simulated bioﬁlm-colonized w
cover dressing (C); after 4–5 days, re-challenge with fresh inoculum (D, E).the most effective in preventing bioﬁlm re-formation following re-
inoculation of the gauze substrate during the test period.
4. Discussion
An expert panel representing the European Society for Clinical
Microbiology and Infectious Diseases (ESCMID) recently published
a guideline for the diagnosis and treatment of bioﬁlm infections, in
which new combinations of antibiotics with bioﬁlm-dissolving
agents were reported to be urgently needed [13]. Management of
bioﬁlm infections is considered to require multi-disciplinary
intervention, involving removal of infected tissues or related
devices, and use of well-penetrating antimicrobial agents in
combination with bioﬁlm dispersal agents [13]. In bioﬁlm-nded by simulated skin and bioﬁlm-colonized gauze applied to create a simulated
ound bed and hydrated with simulated wound ﬂuid (B); application of a secondary
Fig. 3. Antimicrobial/anti-bioﬁlm efﬁcacy of an anti-bioﬁlm silver-containing Hydroﬁber1 dressing (ABSH) in comparison to traditional silver dressings against CA-MRSA.
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ered to be critical in disrupting bioﬁlm and increasing microbial
susceptibility to antibiotics and antiseptics [14]. Consequently, a
multi-faceted approach and use of combination therapies are
clearly needed for effective clinical management of wound bioﬁlm.
Bioﬁlm involvement in wound healing is now an area of active
research, and is considered to be one of the major local factorsFig. 4. Antimicrobial/anti-bioﬁlm efﬁcacy of an anti-bioﬁlm silver-containing Hydroﬁberresponsible for impaired wound healing and infection [4,5]. Non-
healing wounds often fail to respond to antibiotic treatment and/or
antimicrobial dressings, and it is now believed that the presence of
bioﬁlm encourages bacterial tolerance within the wound environ-
ment [3,15]. This prompts the requirement for new therapies that
are able to disrupt wound bioﬁlm and expose associated micro-
organisms in their planktonic form to enable more effective action1 dressing (ABSH) in comparison to traditional silver dressings against P. aeruginosa.
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has been designed with this approach in mind.
It has been previously reported that there is no correlation
between dressing silver content and antimicrobial activity against
planktonic bacteria [16] and the same observation can be made for
anti-bioﬁlm activity from this study. SH demonstrated some anti-
bioﬁlm activity (Fig. 4) and this has been previously reported
elsewhere [8,9]. As the other, higher silver-content dressings
showed no activity, the activity of SH must be due to an intrinsic
property of the base dressing (Hydroﬁber1, a swellable but
insoluble carboxymethylcellulose [CMC]) rather than the silver
component. Indeed a soluble CMC tested in the MBEC model
demonstrated some synergistic anti-bioﬁlm effects.
Consideration of pH may be important for several reasons: (1)
an acidic pH increases the antimicrobial activity of ionic silver
[8,17] and, as shown in the current study, reduces bioﬁlm integrity
thereby increasing microbial susceptibility; (2) chronic wounds are
typically alkaline [18], acute wound healing is associated with
decreasing pH [19], and proteolytic enzymes found in wounds have
peak activities at alkaline or neutral pH [19,20], therefore low pH is
generally preferable; (3) the base ﬁbre of the ABSH dressing is
mildly acidic and can reduce the pH of serum [18]. The inclusion of
EDTA in the ABSH dressing will further enhance the dressing’s pH
buffering ability.
The scale of the synergistic effect seen between silver,
benzethonium chloride and EDTA in the MBEC experiments was
surprising and these observations have been conﬁrmed in an
independent model [21]. This synergy enabled the ABSH dressing
to be formulated with a relatively low concentration of each of
these compounds such that there was no change in tonicity,
toxicity or physical performance from SH. This enhanced,
synergistic effect was maintained in ABSH, in a stringent,
simulated in vitro bioﬁlm wound model, where the ABSH dressing
demonstrated superior anti-bioﬁlm/antimicrobial performance
compared with a variety of traditional silver dressings.
Subsequent to the research, development and in vitro investi-
gation of the ABSH dressing reported here, in vivo and clinical
studies with this dressing have demonstrated favourable out-
comes. In a well-characterised rabbit ear wound bioﬁlm model, the
ABSH dressing was shown to signiﬁcantly reduce polymicrobial
bioﬁlm and promote wound healing versus active and inactive
controls [22]. Clinical safety and effectiveness of the dressing has
also been demonstrated in a study involving 42 subjects with
recalcitrant venous leg ulcers [23], and in a separate clinical
evaluation across Europe and Canada involving 113 recalcitrant
wounds of varied aetiology (49% of which had a duration of greater
than six months, and a majority was suspected as being bioﬁlm-
positive), the ABSH dressing was associated with considerable
improvement in a high proportion of wounds over an average
treatment period of 4.1 weeks [24]. A subsequent clinical evalua-
tion in 29 recalcitrant acute and chronic wounds with suspected
bioﬁlm reported that 34% (10) of the wounds healed completely,
and 90% (26) became smaller in size following application of the
ABSH dressing for a median treatment period of 4.5 weeks [25].
The ABSH dressing is an innovative, next-generation antimi-
crobial wound dressing that has been developed to meet a
previously unmet clinical need. It combines anti-bioﬁlm and
antimicrobial components that work in synergy to disrupt bioﬁlm
and expose associated microorganisms to the broad-spectrum
antimicrobial action of ionic silver. It is anticipated that this
dressing will contribute signiﬁcantly to managing bioﬁlm-imped-
ed wounds and infections, and promoting wound healing in
patients debilitated by recalcitrant wounds. Early experimental
and clinical evidence is encouraging.Conﬂict of interest
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